Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of HCC based on histopathologic findings, or a diagnosis of cirrhosis and a tumor with classical HCC imaging characteristics.~* Sorafenib was the only systemic therapy for HCC and was discontinued for disease progression or intolerance (Main Global and MEE Cohorts only).~* The participant received ≤2 prior systemic therapy regimen, excluding prior sorafenib or chemotherapy, for the treatment of HCC (OLE Cohort only).~* ≥1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 that has not been previously treated with locoregional therapy. A participant with a lesion(s) that has previously been treated with locoregional therapy is also eligible, if the lesion has documented progression after locoregional treatment and is measureable.~* Child-Pugh score \<7 (Child-Pugh Class A).~* Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy.~* Baseline AFP ≥400 nanograms/milliliter.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Resolution of all clinically significant toxic effects of prior therapy.~* Total bilirubin ≤1.5 times upper limit of normal value (ULN), aspartate transaminase (AST) and alanine transaminase (ALT) ≤5 × ULN.~* Creatinine clearance ≥60 milliliters/minute.~* Urinary protein is ≤1+ on dipstick or routine urinalysis or 24-hour urine demonstrating \<1 gram of protein.~* Absolute neutrophil count ≥1.0 × 10\^9/Liter, hemoglobin ≥9 grams/deciliter, and platelets ≥75 × 10\^9/Liter.~* International Normalized Ratio (INR) ≤1.5 and a partial thromboplastin time (PTT) ≤5 seconds above the ULN.~* Surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method.~* If a woman of childbearing potential, a negative serum pregnancy test prior to randomization.~* Willing to provide blood for research. The participant has provided signed informed consent prior to any study specific procedures and is amenable to compliance with protocol schedules and testing.~Exclusion Criteria:~* Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.~* Concurrent malignancy. Participants with carcinoma in situ of any origin and participants with prior malignancies in remission may be eligible with sponsor approval.~* Previous brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.~* History of or current hepatic encephalopathy or clinically meaningful ascites.~* Ongoing or recent hepatorenal syndrome.~* Liver transplant (Main Global and MEE cohorts only; Participants with prior liver transplant may be eligible for OLE cohort).~* Hepatic locoregional therapy following prior systemic therapy or within 28 days prior to randomization.~* Major surgical procedure, traumatic injury, non-healing wound, or peptic ulcer ≤28 days prior to randomization.~* Received radiation to any nonhepatic (for example, bone) site within 14 days prior to randomization.~* Placement of a subcutaneous venous access device within 7 days prior to the first dose of study treatment unless the procedure is judged of low risk of bleeding.~* Enrolled in a clinical trial involving an investigational product or unapproved use of a drug or in medical research judged not to be scientifically or medically compatible with this study.~* Discontinued from study treatment from another clinical trial within 28 days prior to randomization.~* Known allergy to any of the treatment components.~* Uncontrolled hypertension.~* Any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, \<6 months prior to randomization.~* Any bleeding episode considered life-threatening, or any Grade 3 or 4 gastrointestinal bleeding episode in the 3 months prior to randomization requiring intervention.~* Esophageal or gastric varices that require intervention or represent high bleeding risk. Participants with evidence of portal hypertension or prior bleeding must have had endoscopic evaluation within 3 months prior to randomization.~* Gastrointestinal perforation or fistulae within 6 months prior to randomization.~* Symptomatic congestive heart failure (New York Heart Association II-IV), unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia.~* Pregnant or breast-feeding.~* Any medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results. Conditions include but are not limited to:~  * Human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.~ * Active or uncontrolled clinically serious infection. (Participants with chronic viral hepatitis are eligible.)~ * Ongoing or recent history of drug abuse.~ * Uncontrolled hereditary or acquired thrombotic or bleeding disorder.~* Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection.~* Therapeutic dose anticoagulation with warfarin, low molecular-weight heparin, or similar agents.~* Chronic therapy with nonsteroidal anti-inflammatory agents or other anti-platelet agents. Aspirin at doses up to 100 milligrams/day is permitted.~* The participant received prior immunotherapy and is experiencing or has experienced any of the following (OLE cohort only):~  * Any clinically significant Grade ≥3 immune-related adverse event (irAE)~ * Any grade neurologic or ocular irAE~ * Any grade immune-related pneumonitis, cardiomyopathy, or hepatitis~* The participant received prior immunotherapy and at the time of study enrollment, requires steroids or other immunosuppressive agents (OLE cohort only).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramucirumab + Best Supportive Care (BSC) (Type: EXPERIMENTAL): 8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
- Placebo + BSC (Type: PLACEBO_COMPARATOR): Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
- Open Label Ramucirumab + BSC (Type: EXPERIMENTAL): 8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
- Ramucirumab MEE Cohort + BSC (Type: EXPERIMENTAL): 8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
- Placebo MEE Cohort + BSC (Type: PLACEBO_COMPARATOR): Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.

Based on this trial design, predict the completion outcome and termination type (if applicable).